Client Successes

The following are some examples of ZAG/S&W's recent client successes:

Underwriting Representation of International Private Equity Investment Firm

ZAG/S&W acted as counsel to Aegis Capital Corp., sole placement agent in ChromaDex Corporation's closing of common stock sale with gross proceeds of $11.2 million. The sale was made in two offerings, one through a shelf registration statement and the other through a private placement. ChromaDex is a natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex plans to use the net proceeds from the offerings primarily to fund its recently launched BluScience retail consumer line, and for general working capital purposes.

This is the second offering in which ZAG/S&W represented Aegis as part of the firm's underwriting representation practice.

Two Israeli Growth Companies Close Firm Commitment Public Offerings 

Within a two-week period, ZAG/S&W represented two Israeli companies in firm commitment public offerings of their securities on Nasdaq.

ZAG/S&W advised Pluristem Therapeutics Inc. (PSTI – Nasdaq Capital Market) (TASE:PLTR) in a $41 million firm commitment underwritten public offering of its common stock and warrants. Pluristem is a stem-cell company based in Haifa, which is in clinical trials for drugs to treat several severe degenerative, ischemic and autoimmune disorders.

ZAG/S&W also advised On Track Innovations Ltd (OTI) (OTIV – Nasdaq Global Market), a leading innovator in the field of secure contactless microprocessor-based smart card technology, in a $18 million firm commitment underwritten public offering of its ordinary shares.

Helping a NASDAQ-listed, Israeli Biotech Company Raise Funds in the United States

ZAG/S&W assisted client Pluristem Therapeutics Inc. (Nasdaq:PSTI - News) (DAX:PJT) (TASE:PLTR), a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta, with several private placements and securities offerings in the past three years worth more than $15 million. In addition, we assisted Pluristem with its listing on the Tel-Aviv Stock Exchange.

ZAG/S&W’s unique structure, seamless integration between Israel and the United States and strength in the Israeli biotech sector eased the transaction to completion.

Assisting an Israeli Venture Capital Fund in High-Stakes Arbitration 

ZAG/S&W represented an Israeli venture capital fund that was the respondent in an ICDR arbitration with its placement agent regarding an approximately $2.5 million claim. We helped keep the award to the claimant to only $135,000, almost $1 million less than what our client calculated as the best case scenario.

Advising a Publicly Traded Kibbutz Company on U.S. Acquisition 

ZAG/S&W advised Plasson Ltd., an Israeli manufacturer of plastic pipe accessories, in its acquisition of a 77 percent interest in Industrial Pipe Fittings LLC, a Texas-based, privately held company, for $15 million. Plasson is part of Kibbutz Ma’agan Michael, which formed the company in 1964 when a group of agriculturalists decided that farming was becoming more dependent on technology. The Israeli Kibbutz movement was once primarily comprised of farming cooperatives, but now consists of some of the most successful industrial and technology companies in Israel.

ZAG/S&W represented a large international bank in connection with the guarantee by an Israeli manufacturing company of a loan made by the bank to the U.S. subsidiary of the Israeli company.

At ZAG/S&W, we thrive on helping companies grow.